Formycin

Identification

Name
Formycin
Accession Number
DB02281  (EXPT01453)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
6742-12-7
Weight
Average: 267.2413
Monoisotopic: 267.096753929
Chemical Formula
C10H13N5O4
InChI Key
KBHMEHLJSZMEMI-KSYZLYKTSA-N
InChI
InChI=1S/C10H13N5O4/c11-10-6-4(12-2-13-10)5(14-15-6)9-8(18)7(17)3(1-16)19-9/h2-3,7-9,16-18H,1H2,(H,14,15)(H2,11,12,13)/t3-,7-,8-,9+/m1/s1
IUPAC Name
(2S,3R,4S,5R)-2-{7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl}-5-(hydroxymethyl)oxolane-3,4-diol
SMILES
[H][[email protected]]1(CO)O[[email protected]@]([H])(C2=C3N=CN=C(N)C3=NN2)[[email protected]]([H])(O)[[email protected]]1([H])O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
US-methyl-5'-thioadenosine phosphorylaseNot AvailableHuman
U5'-methylthioadenosine/S-adenosylhomocysteine nucleosidaseNot AvailableEscherichia coli (strain K12)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Formycin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Formycin.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Formycin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Formycin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Formycin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Formycin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Formycin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Formycin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Formycin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Formycin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formycin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Formycin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Formycin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Formycin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Formycin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Formycin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Formycin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Formycin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Formycin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Formycin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
447199
PubChem Substance
46507685
ChemSpider
394361
ChEBI
42452
ChEMBL
CHEMBL471524
HET
FMC
PDB Entries
1ifu / 1mrh / 1mrk / 1nc3 / 1sd1 / 1z36 / 2qtt / 3bl6 / 3nm5 / 3ut6
show 6 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.3 mg/mLALOGPS
logP-1.2ALOGPS
logP-2.3ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)11.89ChemAxon
pKa (Strongest Basic)3.38ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area150.4 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity64.16 m3·mol-1ChemAxon
Polarizability25.12 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9715
Blood Brain Barrier+0.8673
Caco-2 permeable-0.7034
P-glycoprotein substrateNon-substrate0.681
P-glycoprotein inhibitor INon-inhibitor0.9671
P-glycoprotein inhibitor IINon-inhibitor0.9912
Renal organic cation transporterNon-inhibitor0.9336
CYP450 2C9 substrateNon-substrate0.9038
CYP450 2D6 substrateNon-substrate0.8214
CYP450 3A4 substrateNon-substrate0.6511
CYP450 1A2 substrateNon-inhibitor0.7932
CYP450 2C9 inhibitorNon-inhibitor0.921
CYP450 2D6 inhibitorNon-inhibitor0.9317
CYP450 2C19 inhibitorNon-inhibitor0.8888
CYP450 3A4 inhibitorNon-inhibitor0.8952
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9402
Ames testNon AMES toxic0.5251
CarcinogenicityNon-carcinogens0.8915
BiodegradationNot ready biodegradable0.9953
Rat acute toxicity2.2480 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9248
hERG inhibition (predictor II)Non-inhibitor0.9303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
C-glycosyl compounds
Alternative Parents
Pentoses / Pyrazolopyrimidines / Aminopyrimidines and derivatives / Imidolactams / Tetrahydrofurans / Pyrazoles / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Dialkyl ethers
show 5 more
Substituents
C-glycosyl compound / Pentose monosaccharide / Pyrazolopyrimidine / Aminopyrimidine / Monosaccharide / Imidolactam / Pyrimidine / Azole / Heteroaromatic compound / Pyrazole
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
formycin (CHEBI:42452)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
S-methyl-5-thioadenosine phosphorylase activity
Specific Function
Catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate. Involved in the breakdown of MTA, a major by-product of polyamine biosynth...
Gene Name
MTAP
Uniprot ID
Q13126
Uniprot Name
S-methyl-5'-thioadenosine phosphorylase
Molecular Weight
31235.76 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Methylthioadenosine nucleosidase activity
Specific Function
Catalyzes the irreversible cleavage of the glycosidic bond in both 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine (SAH/AdoHcy) to adenine and the corresponding thioribose, 5'-methylthiorib...
Gene Name
mtnN
Uniprot ID
P0AF12
Uniprot Name
5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase
Molecular Weight
24353.725 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:12